Evidence map›Paper›PMID 32979072›Full record

Trial reportLung2020

The St. George's Respiratory Questionnaire in Pulmonary Sarcoidosis.

K H Lo, J Donohue, M A Judson, Y Wu, E S Barnathan, R P Baughman, Sarcoidosis T-48 Investigators

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Lung, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. D. Geraint James Lecture: The sarcoidosis saga: what insights from the past will guide us in the future.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2023
    Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

K H LoJanssen Research and Development, LLC, Raritan, USA.
J DonohueThe University of North Carolina, Chapel Hill, NC, USA.
M A JudsonAlbany Medical Center, Albany, NY, USA.
Y WuJanssen Research and Development, LLC, Raritan, USA.
E S BarnathanJanssen Research and Development, LLC, Raritan, USA.
R P BaughmanThe University of Cincinnati Medical Center, 200 Albert Sabin Way, Cincinnati, OH, 45267, USA. bob.baughman@uc.edu.ORCID http://orcid.org/0000-0003-4871-3862
Sarcoidosis T-48 Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleThe Saint George's Respiratory Questionnaire (SGRQ) is a frequently used tool to assess health status in pulmonary disease patients. However, its performance characteristics in sarcoidosis patients are not well characterized.

methodsData from a clinical trial of 138 symptomatic adults with sarcoidosis were used to examine the performance characteristics of SGRQ. Data were available at both baseline and week 24. Other assessments included FVC, FEV1, ATS dyspnea score, Borg's CR 10 dyspnea score, 6-min walk distance (6MWD), and Short Form-36 Physical Component Summary (SF-36 PCS) score.

resultsBaseline SGRQ was 46.8, indicating impaired health status. At baseline, SGRQ total score correlated significantly with % predicted FVC, FEV1, ATS dyspnea score, Borg's CR 10 dyspnea score, 6MWD, and SF-36 PCS (r =  - 0.37, - 0.32, 0.57, 0.40, - 0.55, and - 0.80, respectively, p < 0.001). Change from baseline in SGRQ score also statistically significantly correlated with change from baseline in these parameters at week 24: r =  - 0.25, - 0.20, 0.30, 0.22, - 0.20, - 0.45, respectively (p < 0.05).

conclusionsThe SGRQ correlated with other outcome measures in sarcoidosis initially and with treatment. Improvement in FVC % predicted correlated with improvement in SGRQ. These data suggest the SGRQ may function as a reliable endpoint in clinical sarcoidosis trials.

Indexed as

Health StatusQuality of LifeSurveys and QuestionnairesAdultAntirheumatic AgentsDouble-Blind MethodFemaleHumansInfliximabMaleMiddle AgedOutcome Assessment, Health CarePredictive Value of TestsProspective StudiesReproducibility of ResultsRespiratory Function TestsAntirheumatic AgentsInfliximabQuality of lifeSarcoidosisSF-36SGRQShort form 36

Identifiers

PMID32979072

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.